title: Brain atrophy correlates with functional outcome in a murine model of multiple sclerosis.
abstract: White matter (WM) lesions are the classic pathological hallmarks of multiple sclerosis (MS). However, MRI-based WM lesion load shows relatively poor correlation with functional outcome, resulting in the "clinico-radiological paradox" of MS. Unlike lesion based measures, volumetric MRI assessment of brain atrophy shows a strong correlation with functional outcome, and the presence of early atrophy predicts a worse disease course. While extensive literature exists describing MRI characteristics of atrophy in MS, the exact pathogenesis and the substrate of atrophy-gray vs. WM loss, axonal/neuronal damage vs. demyelination, or a combination of the above-remain unclear. Animal models of atrophy would allow for detailed investigations of the pathomechanism, and would contribute to an enhanced understanding of structural-functional connections in this complex disease. We now report that in the Theiler's Murine Encephalitis Virus (TMEV) model of MS in SJL/J mice, significant brain atrophy accompanies the development of the progressive MS-like disease. We conducted volumetric MRI studies in 8 cases and 4 age, gender- and strain-matched control mice. While in controls we did not detect any brain atrophy, significant atrophy developed as early as 3 months into the disease course, and reached its peak by 6 months, resulting in ventricular enlargement by 118% (p=0.00003). A strong correlation (r=-0.88) between atrophy and disability, as assessed by rotarod assay, was also demonstrated. We earlier reported another neurodegenerative feature in this model, the presence of deep gray matter T2 hypointensity in thalamic nuclei. Future studies utilizing this model will allow us to investigate key components of MRI detectable neurodegenerative feature development, their tissue correlations and associations with functional outcome measures. These studies are expected to pave the way to a better understanding of the substrate of disability in MS models.
authors.affiliation: Mayo Clinic, Department of Neurology, College of Medicine, Rochester, MN 55905, USA. pirko@mayo.edu
authors.forename: I
authors.initials: I
authors.lastname: Pirko
authors.forename: A J
authors.initials: AJ
authors.lastname: Johnson
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: D M
authors.initials: DM
authors.lastname: Lindquist
authors.forename: A K
authors.initials: AK
authors.lastname: Lohrey
authors.forename: J
authors.initials: J
authors.lastname: Ying
authors.forename: R Scott
authors.initials: RS
authors.lastname: Dunn
mesh_terms: D000818:Animals; D001284:Atrophy; D001921:Brain / Q000473:pathology* / Q000503:physiopathology; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D009103:Multiple Sclerosis / Q000473:pathology* / Q000503:physiopathology
references.citation: Neuroimage. 2009 Dec;48(4):637-51
references.pmid: 19589388
references.citation: Annu Rev Biomed Eng. 1999;1:377-99
references.pmid: 11701494
references.citation: J Neuroimmune Pharmacol. 2010 Sep;5(3):355-69
references.pmid: 19894121
references.citation: Ann Neurol. 2001 Jul;50(1):121-7
references.pmid: 11456302
references.citation: Neurosci Lett. 2008 May 30;437(2):121-4
references.pmid: 18440142
references.citation: Arch Neurol. 2004 Feb;61(2):226-30
references.pmid: 14967771
references.citation: Lancet Neurol. 2006 Feb;5(2):158-70
references.pmid: 16426992
references.citation: Radiology. 2008 Mar;246(3):790-5
references.pmid: 18309014
references.citation: Philos Trans R Soc Lond B Biol Sci. 1999 Oct 29;354(1390):1675-86
references.pmid: 10603619
references.citation: Neuroimage. 2006 Sep;32(3):1016-23
references.pmid: 16806982
references.citation: Neurology. 2000 Apr 25;54(8):1689-91
references.pmid: 10762518
references.citation: Curr Opin Neurol. 2002 Jun;15(3):239-45
references.pmid: 12045719
references.citation: Neurology. 2003 Apr 8;60(7):1157-62
references.pmid: 12682324
references.citation: J Neurol Sci. 2009 Jul 15;282(1-2):34-8
references.pmid: 19162280
references.citation: Arch Neurol. 2000 Sep;57(9):1289-92
references.pmid: 10987895
references.citation: J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):141-7
references.pmid: 12122170
references.citation: Neurology. 2007 Feb 27;68(9):634-42
references.pmid: 17325269
references.citation: Lab Invest. 2010 May;90(5):774-86
references.pmid: 20157291
references.citation: J Neuroimaging. 2005;15(4 Suppl):10S-21S
references.pmid: 16385015
references.citation: Acta Neurol Scand. 2000 Aug;102(2):99-105
references.pmid: 10949526
references.citation: J Neuropsychiatry Clin Neurosci. 2002 Winter;14(1):44-51
references.pmid: 11884654
references.citation: N Engl J Med. 2000 Sep 28;343(13):938-52
references.pmid: 11006371
references.citation: Arch Neurol. 2002 Oct;59(10):1572-6
references.pmid: 12374494
references.citation: Springer Semin Immunopathol. 2002;24(2):105-25
references.pmid: 12503060
references.citation: Int MS J. 2004 Dec;11(3):95-9
references.pmid: 15585167